Oral Cancer News – Page 170

Prevalence of Oral HPV Infection Higher Among Men Than Women

CHICAGO -- The overall prevalence of oral human papillomavirus (HPV) infection is approximately 7 percent among men and women ages 14 to 69 years in the United States, while the prevalence among men is higher than among women, according to a study appearing in JAMA. The study is being released early online to coincide with its presentation at the Multidisciplinary Head and Neck Cancer Symposium. Oral HPV infection is the cause of a subset of oropharyngeal [relating to the mouth and pharynx] squamous cell carcinomas (OSCC). Human papillomavirus positive OSCC are associated with sexual behavior in contrast to HPV-negative OSCC that are associated with chronic tobacco and alcohol use. At least 90 percent of HPV-positive OSCC are caused by high-risk (or oncogenic) HPV type 16 (HPV-16), and oral infection confers an approximate 50-fold increase in risk for HPV-positive OSCC. The incidence of OSCC has significantly increased over the last 3 decades in several countries, and HPV has been directly implicated as the underlying cause, according to background information in the article. Although oral HPV infection is the cause of a cancer that is increasing in incidence in the United States, little is known regarding the epidemiology of infection. Maura L. Gillison, M.D., Ph.D., of the Ohio State University Comprehensive Cancer Center, Columbus, and colleagues examined the prevalence of oral HPV infection in the United States. The researchers used data from a cross-sectional study as part of the National Health and Nutrition Examination Survey (NHANES) 2009-2010, a statistically representative sample of the U.S. population. Men and women ages 14 [...]

Charlotte Parker2012-01-26T17:50:44-07:00January, 2012|Oral Cancer News|

Oral temperature changes in head and neck cancer patients predicts side effect severity

Source: American Society for Radiation Oncology The abstract, "Pilot study of functional infrared imaging for early detection of mucositis in locally advanced head and neck cancer reated with chemoradiotherapy," will be presented at the Head and neck Society Meeting in Arizona today. This is a synopsis of that presentation. Slight temperature increases of the oral mucus membranes early in a head and neck cancer patient's chemotherapy and radiation therapy (chemoradiotherapy) treatment is a predictor of severe mucositis later in treatment, according to a study presented at the Multidisciplinary Head and Neck Cancer Symposium, sponsored by AHNS, ASCO, ASTRO and SNM. Mucositis, or mouth sores, is a common side effect of chemoradiotherapy for head and neck cancer that is painful and can be very severe. Physicians cannot predict which patients will have mild mucositis or severe mucositis that would require narcotic pain medication, nutritional support and/or feeding tubes. Researchers in this study hypothesized that using sensitive thermal imaging technology to measure temperature changes of less than one-tenth of a degree early in treatment could predict the severity of mucositis later in treatment. This knowledge could allow for early intervention and potential changes in therapy using a technology that is simple, harmless and non-invasive. Patients receiving chemoradiotherapy underwent baseline and weekly thermal imaging of their oral mucus membranes. All patients displayed an increase in temperature and severe mucositis was found in 53 percent of patients. "If we could predict which patients were going to suffer the greatest toxicity, we could proactively make changes to [...]

Charlotte Parker2012-01-26T15:32:36-07:00January, 2012|Oral Cancer News|

Oral Sex Cancer Virus More Common in Men Than Women, Study Finds

Source: Bloomberg.com About 10 percent of men and 3.6 percent of women are orally infected with human papillomavirus, which is acquired through oral sex and can cause cancer. There are two peaks in the age people are infected -- 30 to 34 and 60 to 64, according to the study published today in the Journal of the American Medical Association. The virus is linked to throat cancer, and is becoming a more common cause of the disease as Americans quit smoking. The virus, called HPV, is the most-common sexually transmitted virus in the U.S., where half the population will be infected at some time in their lives, according to the Centers for Disease Control and Prevention. It is known to cause cervical, vulvar, vaginal, penile and anal cancer. The higher HPV infection rate in men explains why their head and neck cancer rates are greater, said Maura Gillison, a professor at the Ohio State University College of Medicine in Columbus. “This provides pretty strong evidence that the higher infection rate is the reason why,” said Gillison, the study’s lead author, in a telephone interview. “This is a jumping board for additional research.” Besides sex, other demographics associated with oral HPV infection include age, lifetime number of sex partners, and the number of cigarettes smoked each day. The research is the first population-based study to examine how many men and women were infected, Gillison said. Existing Vaccines Though Merck & Co.’s Gardasil and GlaxoSmithKline Plc (GSK)’s Cervarix target genital HPV, it’s [...]

Charlotte Parker2012-01-26T10:10:18-07:00January, 2012|Oral Cancer News|

How online sales and promotion of snus contravenes current European Union legislation

Source: BMJ Journal Abstract Context The European Union (EU) Tobacco Products Directive that bans sales of snus (a form of oral tobacco) in EU countries other than Sweden is currently under review. Major tobacco companies favour the ban being overturned. This study aims to explore compliance with the current ban on snus sales and examines the conduct of online snus vendors, including their compliance with two other EU Directives on excise and tobacco advertising and Swedish legislation banning sales of snus outside Sweden. Methods To determine who is currently distributing snus via the internet in the EU, searches were carried out in Google, followed by searches in the WHOIS and Amadeus databases. Five online test purchases of snus were made in each of 10 EU Member States using a standardised protocol. Feedback from the test purchases and further analysis of the websites accessed for test purchases were used to critically examine snus retailers' conduct. Results The majority of online vendors operate from Sweden and target non-Swedish EU citizens. Test purchases were successfully made in all 10 EU Member States; of 43 orders placed, only two failed. Age verification relied only on self-report. The majority of sales applied Swedish taxes, contrary to EU requirements. Copious sales promotion activities, many price based, are incorporated in these websites contravening the EU regulation, and three test purchases were delivered with gifts. Conclusions Snus is currently being sold on the single market via the internet in contravention of Swedish legislation and three EU Directives. [...]

Charlotte Parker2012-01-25T16:52:56-07:00January, 2012|Oral Cancer News|

Emerging indications: antioxidants for periodontal disease

Source: http://www.dentistryiq.com Author: Edward P. Allen, DDS, PhD Since approximately 10 to 15 percent of adults worldwide suffer from periodontitis at one time or another(1), oral health professionals are constantly challenged with treating patients for existing conditions and helping them prevent future occurrences. Root planing, scaling, and in severe cases, surgical intervention are part of the standard treatment for periodontitis, and antibiotics are used for infection control. However, in recent years, dental health professionals have honed in on the inflammation that accompanies periodontitis. Research shows that inflammation in the oral tissues—especially that associated with periodontitis—can be a factor in chronic illness such as heart and vascular disease, diabetes, arthritis, Alzheimer’s, pregnancy complications, and a growing list of other conditions. The real culprit with inflammation is oxidative stress, a disturbance in the balance of oxidants and antioxidants. Oxidative stress is the result of overproduction of free radicals, unstable molecules that attack tissue cells by “stealing” electrons from other molecules. Although infection is a major trigger for inflammation and oxidative stress, there are numerous other causes, such as poor diet, alcohol consumption and nicotine use or chemical pollutants. In oral tissues oxidative stress can result from dental procedures and from materials used for bleaching, composite fillings, implants, crowns, veneers, and so on. Antibiotics control the micro-organisms that contribute to periodontitis and other infection, but they do not necessarily address the free radicals and oxidative stress that accompany inflammation. Innate defense through natural salivary antibiotics and antioxidants The human body has an innate [...]

Oral Cancer Foundation News Team - A2012-01-21T12:23:49-07:00January, 2012|Oral Cancer News|

Calls for teenage boys to be vaccinated against sexually transmitted virus after throat cancer cases double in UK

Source: www.dailymail.co.uk Author: Charles Walford Boys must be immunised against the most common sexually transmitted virus, health experts have said. The call comes after figures revealed an alarming rise in cancer linked to oral sex in young men. Cases of throat cancer have more than doubled to more than 1,000 a year since the mid-1990s. Previously the figure had been stable for many years. More than 70 per cent of cases are caused by human papilloma virus, compared with less than a third a decade ago. HPV, which can be transmitted during sex and open-mouth kissing, is the main cause of cervical cancer in women, with almost 3,000 women a year in the UK affected. Since 2008 all girls aged 12 to 13 in the UK have been offered a vaccination to protect them from HPV. The decision not to give it to boys too was heavily criticised at the time. Now specialists are urging the Department of Health to review its immunisation programme and offer boys the vaccine too, the Independent reports. They say this would not only ensure both sexes are protected against throat cancer, but it would help reduce the risk of cervical cancer in girls and of other cancers caused by HPV. Research suggests boys are more prone to get throat cancer from oral sex because the virus is found in higher concentrations in the female genital tract. Cancer typically takes 20 to 30 years to develop and the rise in HPV-related throat cancer is being [...]

Oral Cancer Foundation News Team - A2012-01-21T12:16:38-07:00January, 2012|Oral Cancer News|

Big Tobacco led throat doctors to blow smoke

Source: http://med.stanford.edu Author: Tracie White Tobacco companies conducted a carefully crafted, decades-long campaign to manipulate throat doctors into helping to calm concerns among an increasingly worried public that smoking might be bad for their health, according to a new study by researchers at the School of Medicine. Beginning in the 1920s, this campaign continued for over half of a century. “Tobacco companies sought to exploit the faith the public had in the medical profession as a means of reassuring their customers that smoking was safe,” said Robert Jackler, MD, the Edward C. and Amy H. Sewall Professor in Otolaryngology. “Tobacco companies dreamed up slogans such as, ‘Not one single case of throat irritation with Camels;’ then, to justify their advertising claims, marketing departments sought out pliant doctors to conduct well-compensated, pseudoscientific ‘research,’ which invariably found the sponsoring company’s cigarettes to be safe,” Jackler said. “The companies successfully influenced these physicians not only to promote the notion that smoking was healthful, but actually to recommend it as a treatment for throat irritation.” Jackler is the senior author of the study, which was published in the January issue of The Laryngoscope. Hussein Samji, MD, a recent Stanford residency graduate, was his co-author. Using internal documents from tobacco companies from the Legacy Tobacco Document archives, the study’s authors reviewed a wealth of correspondence, contracts, marketing plans and payment receipts that shed light on the industry’s multifaceted, highly effective campaign. Jackler’s ongoing research into the history of tobacco company advertising has resulted in several [...]

Oral Cancer Foundation News Team - A2012-01-21T12:00:08-07:00January, 2012|Oral Cancer News|

Gold nanorods could improve radiation therapy of head and neck cancer

Source:National Cancer Institute Radiation therapy is an important part of head and neck cancer therapy, but most head and neck tumors have a built-in mechanism that makes them resistant to radiation. As a result, oncologists have to deliver huge doses of X-rays to the patient, damaging surrounding tissues and producing significant side effects. To overcome this resistance, researchers at the State University of New York (SUNY) at Buffalo and the University of Southern California (USC) have developed a nanoparticle formulation that interferes with the resistance mechanism, and as a result, increases the efficacy of radiation therapy in a mouse model of head and neck cancer. Reporting its work in the journal Integrative Biology ("Gold nanorod–sphingosine kinase siRNA nanocomplexes: a novel therapeutic tool for potent radiosensitization of head and neck cancer"), a research team headed by Paras Prasad of SUNY Buffalo and Rizwan Masood of USC's Keck School of Medicine describes how it used gold nanorods to deliver a small interfering RNA (siRNA) molecule to head and neck tumors. This siRNA molecule blocks the production of a protein known as sphingosine kinase 1 (SphK1). Previous work by the USC team had shown that this protein prevents radiation-damaged cells from undergoing apoptosis, the cell death program triggered in healthy cells when they age or experience major damage. RNA interference, which uses siRNAs to reduce the production of specific proteins, has shown promise for treating cancer and other diseases, but these molecules are readily degraded in the blood stream. To overcome this problem, [...]

Charlotte Parker2012-01-19T17:08:52-07:00January, 2012|Oral Cancer News|

Fatal Infusion Reactions to Cetuximab: Role of Immunoglobulin E–Mediated Anaphylaxis

Source: Journal of Clinical Oncology To the Editor: In Journal of Clinical Oncology, Tronconi et al1 report a fatal hypersensitivity reaction to cetuximab in a 63-year-old patient with metastatic colon cancer and outlined a 0.1% incidence of death in the literature. We greatly acknowledge the authors' desire to communicate the risk of fatal anaphylactic reaction with cetuximab. Over the past 2 years in our center in Tours, France, four instances of grade 4 anaphylactic reactions occurred in patients treated for head and neck cancer (locally advanced or metastatic), with one immediately fatal; another patient died within 5 days (unpublished data). Seven lethal anaphylactic reactions were registered in a pharmacovigilance survey in France, based on spontaneous declarations (Grandvuillemin et al, manuscript in preparation). Anaphylaxis to cetuximab is a problem that merits serious clinical attention. In the authors' words, “the pathogenic mechanisms underlying the development of this phenomenon remain to be elucidated.”1 They raise the hypothesis of immunoglobulin E (IgE) –independent mechanisms, even in the context of a paradoxic atopic history. Moreover, Tronconi et al suggest that the field “search for reliable risk factors that can facilitate the safe selection of patients as candidates for cetuximab-based treatment.”1 These comments are quite surprising, because they do not integrate major contributions that have been previously published. Indeed, it has been known for 3 years that anaphylaxis to cetuximab is the result of antidrug IgE antibodies present in patient serum before therapy.2 These IgE antibodies are directed against galactose-α-1, 3-galactose (α3Gal) residues, present in the [...]

Charlotte Parker2012-01-19T10:24:57-07:00January, 2012|Oral Cancer News|

FDA to weigh safety of tobacco lozenges, strips

Source: USA Today They may look and smell a lot like candy, but dissolvable, smokeless tobacco products aren't for kids. The safety and risks of "dissolvables" are the subject of a three-day U.S. Food and Drug Administration meeting this week. This is a concept of the Camel Orbs a smokeless tobacco product by RJ Reynolds company. The company is test marketing Camel Orbs, Camel Strips and Camel Sticks in two cities. "Dissolvables" are flavored mints, strips and sticks of smokeless tobacco. These products are not stop-smoking aids. Instead, they are designed to allow people to satisfy their cravings for nicotine in places where smoking is banned. R.J. Reynolds Tobacco Co. is test marketing Camel Orbs, Camel Strips and Camel Sticks in two cities, and Star Scientific Inc., is marketing two other dissolvable tobacco products, Ariva and Stonewall. Many public health advocates are concerned about the risks these products pose to children and teens, namely possible addiction and nicotine poisoning. "If you wanted to design a product that would appeal to youth and addict younger adolescents and adults to nicotine, this would be it," said Dr. Jonathan Winickoff, a pediatrician at Massachusetts General Hospital in Boston. "These products are designed to look like a candy and addict the user permanently." Teens can pop these products without any of the telltale signs of smoking cigarettes or the mess associated with snus, which are teabag-like pouches placed between the upper lip and gun. Before long, he said, they're addicted. Another worry is accidental [...]

Charlotte Parker2012-01-19T10:17:01-07:00January, 2012|Oral Cancer News|